Weiss Asset Management
SAGE icon

Weiss Asset Management’s Sage Therapeutics SAGE Stock Holding History

Weiss Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,620
Closed -$370K – 485
2018
Q3 		$370K Hold
2,620
– – 0.03% 125
2018
Q2 		$410K Hold
2,620
– – 0.04% 121
2018
Q1 		$422K Hold
2,620
– – 0.03% 124
2017
Q4 		$432K Buy
+2,620
New +$254K 0.04% 136

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
OppenheimerFunds
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Weiss Asset Management's SAGE Position: Q4 2018 in Review

Weiss Asset Management sold out of Sage Therapeutics (SAGE) in Q4 2018, closing a stake of 2,620 shares — an estimated $370K sold.

Weiss Asset Management first reported a position in SAGE in Q4 2017 and held it in 4 quarters. The position peaked at $432K in Q4 2017. 249 funds tracked by Wall St. Rank hold SAGE as of Q4 2018.

  • Weiss Asset Management reported no remaining Sage Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Weiss Asset Management sold 2,620 Sage Therapeutics shares in Q4 2018, an estimated $370K.
  • Weiss Asset Management first reported a position in Sage Therapeutics in Q4 2017 and held it in 4 quarters.
  • Weiss Asset Management's Sage Therapeutics position peaked at $432K in Q4 2017.
  • 249 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2018.

Based on Weiss Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.